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Edited by Veli-Pekka LehtoAbstract Using the C6 glioma cell as a paradigm, we found
that (i) the clonogenicity of C6 cells is several orders of magni-
tude higher than the percentage of SP cells; (ii) non-SP cells
are able to generate SP cells, and conversely SP cells generate
non-SP cells; (iii) non-SP sorted cells behave as tumorigenic
cells. Hence, in C6 cells cultured in serum-containing medium,
SP cells can be generated from non-SP cells. This dynamic equi-
librium explains in C6 cells the maintenance of the SP phenotype
with cell passaging and demonstrates the existence of tumori-
genic non-SP cells.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the hematopoietic system, stem cells (HSC) have been en-
riched as a side population (SP) on their ability to exclude the
ﬂuorescent vital dye Hoechst 33342 [1]. This Hoechst eﬄux
phenomenon, initially described as a reliable tool for HSC
enrichment, has received particular attention when it became
apparent that this property is shared with stem cells found in
several other tissues [2]. Afterwards, several studies have pro-
vided evidence for the existence of a distinct SP in tumor cell
lines such as C6, U373, MCF7, HeLa and many other cancer
cell lines [3–11]. Moreover, SP cells have also been found in
primary neuroblastoma tumor cell samples [4], and leukemic
SP cells have been detected in the bone marrow from patients
with acute myeloid leukemia [12]. According to the cancer
stem cell paradigm, these SP cells generate both SP and non-
SP cells, whereas non-SP cells produce non-SP cells only
[3,4,10,11]. Moreover, because of their higher tumorigenicity
or proliferative potential these SP cells are assimilated to
stem-like cancer cells [3–11]. Hence, the SP phenotype may
prove invaluable for the identiﬁcation and characterization
of cancer stem cells from cell lines and tumors, a point of cru-
cial concern if these cells are the only cells capable of maintain-
ing the growth of the tumor [13]. However, even if in a given
cell line SP cells are described to be more tumorigenic that
non-SP cells, there is no correlation between the presence of*Corresponding author. Fax: +33 4 76 76 56 19.
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doi:10.1016/j.febslet.2007.02.071SP and tumorigenicity in general. Thus, SP is undetectable in
the highly tumorigenic prostate tumor cells PPC-1, but is de-
tected in the prostatic LAPC9 cell line which behaves interme-
diate tumorigenicity [5]. Likewise, SP cells are found in the low
tumorigenic breast cancer cell line MCF7, but remain unde-
tectable in the highly tumorigenic MDA-MB231 and MDA-
MB435 breast cancer cells [5]. Another intriguing point is that
the little percentage of SP cells found in cancer cell lines har-
bouring a detectable SP (0.05–0.4%) seems low compared to
their expected clonogenicity. In an attempt to elucidate these
paradoxical ﬁndings, we decided to reinvestigate the relation-
ship existing between SP cells and cancer stem-like cells using
the C6 glioma cell as a paradigm.2. Material and methods
2.1. Cell culture
Rat glioma C6 cells (ATCC CCL107) [14] and the clonal derivative
C6.9 cell line [15] were cultured in complete medium consisting in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) containing high glucose
and pyruvate, and supplemented with 10% foetal bovine serum
(FBS), and 2 mM L-glutamine, all purchased from Gibco-Invitrogen.
Cells were maintained at 37 C in a humidiﬁed 5% CO2 atmosphere.
2.2. Establishment of clonal population of C6
A suspension of C6 cells (passage 48) was obtained from subconﬂu-
ent culture by trypsinization. Cells were isolated by the mean of
microscopic examination and micromanipulation, then distributed in
96-wells plate containing complete medium supplemented with condi-
tioned medium of C6 cells. Each well was then checked for the presence
of a solitary cell. After ampliﬁcation, cells were tested for long-term
proliferation and tumorigenicity.
2.3. Flow cytometry
For side population analysis and isolation, cells were retrieved from
subconﬂuent culture by trypsinization, resuspended at 106 cells/ml in
prewarmed DMEM containing 2% FBS, 10 mM Hepes, then incu-
bated for 90 min at 37 C with Hoechst 33342 (2.5 lg/ml ﬁnal concen-
tration, Sigma) with intermittent mixing. Control cells were given
Verapamil (50 lM ﬁnal concentration, Sigma) to block pumps that ex-
clude the Hoechst. At the end of incubation, cells were spun down in
the cold and resuspended in cold HBSS (purchased from Gibco-Invit-
rogen) containing 2% FBS and 10 mM Hepes.
Cytometric analysis was performed on FACS Vantage SE. Hoechst
dye was excited at 351 nm by UV laser and its ﬂuorescence detected at
two wavelengths using 424/44 (Hoechst blue) and 630/22 (Hoechst red)
band pass ﬁlters. Dead cells were excluded from the plots based on
propidium iodide staining. Data acquisition was achieved on 106 cells
for SP analyses and 105 cells for cell sorting. Data were reanalyzed with
FCS Express 2 software (De Novo Software, Thornhill, Canada).
For FACS analyses, the gates were placed using the verapamil
control tube. Hence, only cells with Hoechst eﬄux potential were in-
cluded in the SP gate. Conversely, the non-SP gate only included cells
without eﬄux potential. Non-SP cell population included cycling andblished by Elsevier B.V. All rights reserved.
Table 1
Percentage of SP cells in low and high passages C6 cells, and in C6.9
cellsa
% SP cells in total population (n = 5)
C6 low passage (p42–p50) 0.076 ± 0.045
C6 high passage (p53–p76) 1.95 ± 0.68
C6.9 UD
aMean % of side population detected in ﬁve independent experiments.
UD = undetectable.
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to the right side of the histogram to ensure that SP cells were not in-
cluded in this cell population (see Fig. 2). Immediately after puriﬁca-
tion, sorted cells were either plated in complete medium for
determination of in vitro growth potential and subsequent SP analysis,
or either resuspended in DMEM for injection into nude mice.
2.4. Tumorigenicity
For tumor experiments, various numbers of cells resuspended in
100 ll of DMEM were injected subcutaneously into female nude mice
(8–12 weeks old, Harlan). Tumorigenicity was evaluated by tumor inci-
dence (i.e. number of tumor-bearing animals/number of animals in-
jected) and latency (i.e. time of apparition of a palpable tumor).
Animals without tumor uptake were killed 4 months after cell injection.
2.5. RT-PCR analysis
Total RNA from either SP or non-SP cells were ampliﬁed using Fast
Lane cell cDNAandOne stepRT-PCRkits fromQiagen.RT-PCRwere
performed using the following primers: mdr1: 5 0-GCAAAGCTGGA-
GAGATCCTCACCAAG-30 and 5 0-CAACATTTTCATTTCAAC-
CACTCCTGC-3 0; ABCG2/bcrp1: 5 0-CCAGTTCCATGGCCCTGG-
CCATAG-3 0 and 5 0-CAGGGCCACATGATTCCTCCACAG-30;
gapdh: 5 0-CATGACCACAGTCCATGCCATCAC-3 0 and 5 0-CCCT-
CAGATGCCTGCTTCGCCTTC-3 0. PCR parameters were 94 C for
30 s, 60 C for 30 s, and 72 C for 30 s. Numbers of cycles were 40 for
mdr1 and ABCG2/bcrp1, and 38 for gapdh. Genomic DNA contamina-
tion was controlled by PCR of non-reverse transcribed RNA (data not
shown).Fig. 1. Side population (SP) analysis of C6 and C6.9 cells. Cells were stained
each panel. Addition of verapamil inhibits Hoechst eﬄux from both SP an
independent experiments. (A) C6 cells, passage 50; (B) C6 cells, passage 57;3. Results
3.1. SP analysis of C6 and C6.9 glioma cells
We ﬁrst investigated the presence of SP cells in the C6 gli-
oma cell line cultured in serum containing medium. As previ-
ously reported by others [3], a SP was detected in C6 cells
(passage 50) cultured in serum-containing medium (Fig. 1A).
Cell passaging increases the percentage of SP cells (Fig. 1B
and Table 1). Interestingly, when we deﬁned SP cells by their
verapamil sensitivity to eﬄux Hoechst 33342, we also detected
an additional cell population whose staining is aﬀected by
verapamil. This cell population, we named ‘‘upper-SP’’with Hoechst 33342. The SP and ‘‘upper-SP’’ regions are indicated on
d ‘‘upper-SP’’ cells. FACS proﬁles are representative of at least three
(C) C6.9 cells.
Table 2
Tumor incidence indicates the number of tumor-bearing animals/number of animals injected
A
Number of cells injected Tumor incidence (latency)
500 C6.9 4/4 (13–16 days)
500 C6 4/4 (13–18 days)
B
Number of C6 sorted cells injected Tumor incidence (latency) for SP cells Tumor incidence (latency) for NSP cells
50000 ND 3/3 (6 days)
5000 ND 3/3 (11–13 days)
500 2/3 (11–15 days) 3/3 (13–18 days)
4/4 (10–19 days) 4/4 (14–19 days)
Latency refers to the time of apparition of a palpable tumor. ND, not determined.
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content (aneuploid cells, or cells in S and G2 phases). SinceFig. 2. Generation of SP cells from non-SP C6 glioma cells. Fluctuation of th
incubated with Hoechst 33342 and FACS analyzed. The gates shown were us
were undetectable in the non-SP cell population whereas the SP sorted cell po
from C6 non-SP or SP sorted cells were expanded for two weeks, stained with
non-SP and SP cells. Likewise, cell cultures expanded from C6 SP sorted cells
and non-SP cells.normal stem cells are largely quiescent and euploid, this
upper-SP may not have been detected previously and coulde SP/non-SP phenotype in the C6 glioma cell line. C6 glioma cells were
ed to isolate SP or non-SP cells. (A) After three sorting rounds SP cells
pulation still contained very few non-SP cells (0.08%). (B) Cell cultures
Hoechst and FACS analyzed. Non-SP cells from C6 cell line generate
were stained with Hoechst and FACS analyzed and contained both SP
mdr1
bcrp1
1 2
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was detected in the C6.9 cells (Fig. 1C and Table 1), a subclone
obtained by limited dilution of the original C6 cell line and
previously used to investigate the eﬀect of vitamin D and can-
abinoids on glioma cell growth [15,16].
3.2. Tumorigenicity of C6.9 cells
According to the assumption that SP cells are more tumor-
igenic than non-SP cells, we reasoned that C6.9 cells should be
less tumorigenic than the C6 parental cells. To test this point
we investigate the tumorigenicity of C6.9 cells, and found that
500 injected C6.9 cells or C6 cells were suﬃcient to induce tu-
mor growth in nude mice (Table 2A). Hence, C6.9 was as
tumorigenic as the parental C6. Thus, this data raised again
the paradox of the existence of a tumorigenic cell line with
undetectable SP.
3.3. C6 SP and non-SP cells are similarly tumorigenic
In a ﬁrst set of experiments we considered, according to the
data presented in Fig. 1A, that the percentage of SP cells in low
passage C6 cell cultures was less than 1%. Hence, assuming
that non-SP cells were mainly non-tumorigenic cancer cells un-
able to give rise to ‘‘cancer stem cells’’, we expected that the
probability for one isolated single C6 cell to establish a tumor-
igenic clonal culture should be low. Therefore we addressed the
clonogenicity of C6 cells (passage 48; SP 0.2%). In these
experiments, single C6 cells were plated at a density of one cell
per well in conditioned culture medium as described in Section
2. Using these experimental conditions, cultures were consis-
tently established for almost each single plated cell (28/29).
All these clones can be maintained in culture for at least 4
months and are tumorigenic when injected in nude mice (data
not shown). To further investigate the relationship between SP
and tumorigenicity, SP and non-SP cells were sorted from C6
glioma cells (passage 50). Injection of 500 of these SP or non-
SP sorted cells in nude mouse induced tumor formation (Table
2B). These data conﬁrms that non-SP C6 cells behave as
tumorigenic cells.
3.4. Non-SP C6 cells generate SP cells
We next challenged the assumption that non-SP cells cannot
generate SP cells. For this purpose non-SP C6 cells were
sorted. After three consecutive rounds of cell sorting, SP cells
were undetectable in the non-SP isolated cell population
(Fig. 2A). These non-SP cells were then expanded for 2 weeks,
and FACS analyzed. Data presented in Fig. 2B demonstrate
that the non-SP C6 cells generated SP cells.
3.5. C6 SP cells express ABCG2/bcrp1
ABCG2/bcrp1 is the major drug transporter conferring the
SP phenotype [17]. It is expressed in a wide variety of normal
and cancer stem cells [1,3–5,17]. Results presented in Fig. 3
demonstrate that the expression of this gene is detected in SP
cells only. In addition, both SP and non-SP cells expressed
mdr1, a gene coding for another ATP-binding cassette (ABC)
transporter involved in drug resistance (Fig. 3) [3].
gapdh
Fig. 3. Expression of mdr1 and ABCG2/bcrp1 in SP and non-SP C6
cells. RNA from SP (lane 1) and non-SP (lane 2) cells were reverse
transcribed and resulting cDNAs ampliﬁed as described in 2. ABCG2/
bcrp1 expression correlates with SP phenotype.4. Discussion
Our results conﬁrm the presence of SP cells in the C6 glioma
cell line and the expression of the ABCG2/bcrp1 drug resis-tance gene in SP cells only [3]. In addition to being a molecular
determinant of the side population phenotype [17], ABCG2/
bcrp1 has been shown to eﬄux over 20 diﬀerent chemothera-
peutic agents such as methotrexate, topotecan, mitoxantrone
and doxorubicin [18]. This suggests that C6 SP cells should
have an increased resistance to these chemotherapeutic agents.
Interestingly, we also demonstrate that, in the presence of fetal
bovine serum, non-SP C6 cells proliferate and do generate SP.
Moreover, we found no diﬀerence in tumorigenicity between
SP and non-SP cells. These results may appear at odds with
previous ﬁndings showing that culture of non-SP C6 cells do
not generate SP cells [3] and that SP cells are more tumorigenic
than non-SP cells [3,5,10,11]. However, several explanations
can be provided to account for this discrepancy. For example,
it is known that SP proﬁles from diﬀerent laboratories can vary
and the SP gating is quite arbitrary [19]. On the other hand,
diﬀerences between early and late passage C6 cell cultures have
been repeatedly reported [20–22]. All our experiments have
been initiated between passage 42 and 50. Unfortunately, the
cell passage number of C6 cells used in previous cancer stem
cell studies is rarely indicated [3]. Another possible reason
for the observed discrepancy concerns the cell culture condi-
tions. It is noteworthy that all of our experiments have been
performed in the presence of fetal bovine serum instead of
the serum-free medium used by Kondo et al. [3]. Thus, a pos-
sible explanation is that, in the C6 cell line, the culture medium
used by Kondo et al. allows both the growth of SP cells and
the generation of non-SP cells, but is suboptimal for the gener-
ation of SP cells from non-SP cells. It has been previously re-
ported that C6 cells are transformed glial stem/progenitor cells
[23,24]. Therefore, extracellular signals provided by fetal bo-
vine serum could induce non-SP cells to revert to SP cells,
and this potential could be a feature of transformed glial
stem/early progenitor cells. Interestingly, this ﬂuctuating phe-
notype has been described for oligodendrocyte precursor cells
that can be reprogrammed to become multipotent CNS stem
cells [25], and for the muscle cell line C2C12 and a thyroid can-
cer cell line in which SP cells arise from non-SP cultures
[26,27]. Hence, our results conﬁrm the possibility for non-SP
cells to regenerate SP cells, and demonstrate the existence in
the C6 cell line of a dynamic equilibrium between these two cell
populations (Fig. 4). These data do not necessarily challenge
previous results demonstrating that SP cell analysis can be
used to isolate cancer stem cells, but conﬁrm that in some
Fig. 4. SP and non-SP in cell cultures: Two hypothetical models. (A)
According to the prevalent model, only a small subset of cancer cells
are SP cells. They self-renew, proliferate extensively, form new tumors
and generate low tumorigenic non-SP cancer cells. (B) Our results
suggest that in serum-containing medium, cell populations SP cell and
non-SP cell populations exist in a dynamic equilibrium. Consequently
both have the capacity to proliferate extensively and to form new
tumors. We suggest the origin of the primitive cancer initiating cell
(stem cell, early progenitor, more mature progenitor, terminally
diﬀerentiated cell) will determine which model is relevant for a given
cell line. Moreover, in the (B) model, microenvironment cues could
shift the equilibrium and generate a diﬀerentiation process leading to
the appearance of non-tumorigenic, non-SP cells. In both models non-
SP tumorigenic cells may appear as a consequence of continual
selection for genetic or epigenetic variants.
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[26,27]. Thus, it is possible that the ﬂuctuating phenotype ob-
served here is a feature of highly tumorigenic and proliferative
cancer cells such as C6 cells when they are cultured in serum-
containing medium. In the C6 cell line, cell passaging or sub-
cloning, genomic instability as well as epigenetic events can
lead to the selection of mutants such as C6.9 cells that have lost
this ﬂuctuating phenotype in serum-containing medium. These
non-SP cells can therefore be viewed as ‘‘secondary’’ tumori-
genic cells and are indistinguishable from cancer stem cells
on the basis of clonogenicity and tumorigenicity assays.
Whether or not these ‘‘secondary’’ tumorigenic cells mimic
the progression of the tumor in vivo, or are in vitro artefacts
remains an open question. Overgrowth of these ‘‘secondary’’
tumorigenic cells in cell culture could lead to the depletion of
the original cancer stem cells pool and explain the existence
of tumorigenic cancer cell lines with undetectable SP cells.
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